Product Design

When the Food and Drug Administration's (FDA) Quality Management System Regulation (QMSR) took effect. QMSR amended 21 CFR 820 with a framework aligned to ISO 13485:2016. Buried in that shift is a quieter change, one that matters enormously if you're developing medical devices for both the US and Europe. Usability engineering stopped being two separate conversations.

A clinician using a medical device interface should not have to pause, guess or recover from preventable confusion. Every screen needs to assist them in making the right decision safely, quickly and with confidence.

A test lab is quiet, well-lit and interruption-free. Real hospitals aren't. IDE's Minimum Viable Chaos method deliberately breaks that illusion, testing devices under real clinical noise, before regulators or patients do.

Kent DiasAbeygunawardena on why regulatory clearance gets you into market, but clinician adoption is what decides commercial success, and how Human Factors Engineering (HFE) is now shaping devices from day one, not validating them at the end.

IDE Group has announced OptoSleep as the Grand Prize Winner of the 2025 Building Better Futures for Health (BBFH) Challenge final event held during the MTAA MedTech Conference in Sydney

IDE Group has announced the finalists for the 2025 Building Better Futures for Health (BBFH) Challenge, a national initiative designed to accelerate the commercialisation of early-stage medical technologies and strengthen the foundations of Australia’s MedTech innovation ecosystem

IDE Group has launched the 2025 Building Better Futures for Health (BBFH) Challenge, a national program designed to accelerate the development of early-stage medical technologies. Delivered in collaboration with the Medical Technology Association of Australia (MTAA) MedTech Compass membership initiative

IDE Group has announced that its purpose-built ophthalmic auto-injector, OKO™, has received AU$1,200,000 grant through the Targeted Translation Research Accelerator (TTRA) program for Diabetes and Cardiovascular Disease to advance the commercialisation of OKO™.

IDE Group has been at the forefront of medical innovation for over two decades, partnering closely with leading healthcare companies and emerging disruptors to bring groundbreaking products and businesses into the market.

IDE Group announces OKO, the first auto-injector designed for ophthalmology, offering 59x greater dosing accuracy, 45% faster procedures, and 78% cost savings. Transforming retinal disease treatment.